Cartesian Therapeutics (RNAC) Accumulated Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Accumulated Expenses data on file, last reported at $10.2 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $10.2 million, up 10.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.2 million (up 10.48% YoY), and the FY2025 annual result was $9.5 million, down 21.35% from the prior year.
• Accumulated Expenses climbed to $10.2 million in Q1 2026 per RNAC's latest filing, from $9.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $15.6 million in Q4 2023 and troughed at $7.7 million in Q3 2025.
• A 5-year average of $10.9 million and a median of $10.2 million in 2026 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses surged 39.56% in 2022, then tumbled 30.69% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $14.1 million in 2022, then increased by 10.57% to $15.6 million in 2023, then slipped by 22.45% to $12.1 million in 2024, then retreated by 21.35% to $9.5 million in 2025, then rose by 6.98% to $10.2 million in 2026.
• Business Quant data shows RNAC's Accumulated Expenses at $10.2 million in Q1 2026, $9.5 million in Q4 2025, and $7.7 million in Q3 2025.